Given the potential antigen-presenting advantages of CD47 blockade in improving adaptive immunity function when combined with CD8+ T cells [90], further research into the combination of CD47 blockade with CAR-T cells for cancer therapy is critical. This evidence concerns the gene CD8A and cancer.